Related Experiment Video
Updated: Jul 19, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice
Sara McEntee1, Yifei Liu2, Tahar Mahmoudi3
1Walgreens Health-System Pharmacy #10845, Kansas City, MO, USA.
Abstract:
The treatment options for hepatitis C have undergone noteworthy advancements since direct-acting antivirals (DAAs) were introduced. The selection of a DAA therapy depends on the patient's genotype, treatment history, concomitant comorbidities, and concurrent medications. Pharmacists have a pivotal role in providing clarification and recommendations in selecting appropriate, individualized DAAs for patients. This commentary aims to (1) provide an overview of DAAs on the market for hepatitis C, and (2) describe the implication for the care of patients with hepatitis C in a community pharmacy. Community pharmacists can establish a workflow to recommend appropriate DAA therapy, identify drug interactions, and improve medication adherence and compliance with lab appointments.
Related Concept Videos
Retrovirus Life Cycles
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hepatic Drug Excretion: Influencing Factors
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hepatic Drug Clearance: Role of Transporters
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

